Rights Offering at 0.8 New Shares per Existing Share After 3:1 Reverse Stock Split

NGeneBio decided to conduct a 3:1 reverse stock split effective June 24, 2026, followed by a rights offering allocating 0.8000820895 new shares per existing common share
The issue price will be set at a 25% discount to the market price, with a maximum discount of 40% for the final price
Subscription period for existing shareholders is August 13–14, 2026; general public subscription is August 19–20, 2026. Lead underwriter is Sangsangin Securities
The purpose of the fundraising is not disclosed, leaving the specific use of proceeds unknown
Rights certificates will be issued as electronic securities and listed on the Korea Exchange, expected listing period from July 29 to August 4, 2026